Skip to main content

NICE IDs

11/10/2021
ID3764: Setmelanotide for treating obesity caused by LEPR or POMC deficiency
11/10/2021
ID1676: Nivolumab for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer
01/06/2021
ID3835: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
01/06/2021
ID1605: Enzalutamide for treating hormone-sensitive metastatic prostate
03/12/2020
ID1669: Secukinumab for treating moderate to severe plaque psoriasis in children and young people
30/11/2020
ID1680: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
30/11/2020
ID1622: Baricitinib for treating moderate to severe atopic dermatitis
30/11/2020
ID2728: Bupivacaine–meloxicam for treating postoperative pain
23/11/2020
ID1598: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
06/11/2020
ID3878: Upadacitinib for previously treated moderate active rheumatoid arthritis
06/11/2020
ID1400: Upadacitinib for treating severe rheumatoid arthritis
30/10/2020
ID740: Liraglutide for managing overweight and obesity
23/10/2020
ID1443: Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer
14/10/2020
ID3732: Bulevirtide for treating chronic hepatitis D
12/10/2020
ID885: Short bowel syndrome - teduglutide
12/10/2020
ID1572: Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484)
12/10/2020
ID1559: Nivolumab for previously treated squamous non-small-cell lung cancer (CDF Review TA483)
12/10/2020
ID1577: Lung cancer (non-small-cell, EGFR and T790M positive, metastatic) - osimertinib (CDF Review of TA416)
12/10/2020
ID3786: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (rapid review TA621)
10/09/2020
ID1532: Ixekizumab for treating axial spondyloarthritis after NSAIDs
Follow AWTTC: